Learn about the global oligonucleotide therapy market through The Business Research Company, which provides information on oligonucleotide therapy market size, oligonucleotide therapy market drivers and restraints, oligonucleotide therapy market players, the COVID-19 impact on the oligonucleotide therapy market, and more.

The global oligonucleotide therapy market size is expected to grow from $0.98 billion in 2021 to $1.10 billion in 2022 at a compound annual growth rate (CAGR) of 12.2%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The oligonucleotide therapy market is expected to reach $1.86 billion in 2026 at a CAGR of 14.0%.

The rise in the number of cancer cases across the globe is likely to contribute to the growth of the oligonucleotide therapy market during the forecast period.

Request A Sample For The Global Oligonucleotide Therapy Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3398&type=smp

The oligonucleotide therapy market consists of sales of oligonucleotide therapy related services by entities (organizations, sole traders and partnerships) that manufacture oligonucleotide therapy products. Oligonucleotide therapy uses synthetic oligonucleotides, which can be artificially produced in labs, to inactivate disease-causing genes. Only goods and services traded between entities or sold to end consumers are included.

Global oligonucleotide therapy market segments include:

By Type: Antisense Oligonucleotide, Aptamer, Other

By Application: Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney Diseases, Others

By End-User: Hospitals, Research Institutes

By Geography: The market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa.

The developers and providers of the oligonucleotide therapy market are investing in research and development to remodel the design of therapy to reduce its side effects on patients. The new and innovative oligonucleotides allow precision medicine approaches and can be designed to selectively target any gene with minimal side effects. It also helps in targeting patient-specific sequences that are causative of rare diseases.

TBRC’s oligonucleotide therapy market report covers:

Major Market Players: Alnylam Pharmaceuticals Inc., Biogen Inc., Dynavax Technologies Corp., Ionis Pharmaceuticals Inc., Merck & Co. Inc., Miragen Therapeutics Inc., PCI Biotech Holdings ASA, Sarepta Therapeutics Inc., Jazz Pharmaceuticals and Bausch & Lomb.

Regions: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.

Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Time Series: Five years historic (2016-21) and ten years forecast (2022-2026-2031)

The Oligonucleotide Therapy Global Market Report 2022 –Market Size, Trends, And Global Forecast 2022-2026 is one of a series of new reports from The Business Research Company that provides oligonucleotide therapy market overviews, analyzes and forecasts market size, share, oligonucleotide therapy market players, oligonucleotide therapy market segments and geographies, leading competitor revenues, profiles and market shares.

TBRC’s oligonucleotide therapy market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.

Here is a list of similar reports from The Business Research Company:

Nucleic Acid Based Gene Therapy Market 2022

Gene Therapy Global Market Report 2022

Cell And Gene Therapy Global Market Report 2022

Interested to know more about The Business Research Company?

The Business Research Company has published over 1000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets.

Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: info@tbrc.info

Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company

Follow us on Twitter: https://twitter.com/tbrc_info

Check out our Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: